Innate Pharma Confirms $75M 'At-The-Market' Equity Offering Program
Ticker: IPHYF · Form: 6-K · Filed: Feb 6, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $75.0 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: equity-offering, at-the-market, capital-raise, dilution-risk
TL;DR
**Innate Pharma can sell up to $75M in new shares, potentially diluting current investors.**
AI Summary
Innate Pharma SA filed a 6-K on February 6, 2024, confirming its ongoing "at-the-market" equity offering program established on April 26, 2023, with Jefferies LLC. Under this program, Innate Pharma can sell up to $75.0 million worth of American Depositary Shares (ADSs), each representing one ordinary share, through Jefferies as its sales agent. This matters to investors because it indicates the company's potential to raise capital by issuing new shares, which could dilute the value of existing shares if a significant portion of the $75.0 million offering is utilized.
Why It Matters
This filing confirms Innate Pharma's ability to raise up to $75.0 million by selling new shares, which could dilute existing shareholders' ownership and impact share price.
Risk Assessment
Risk Level: medium — The potential for share dilution from the $75.0 million offering represents a medium risk to existing shareholders.
Analyst Insight
Investors should monitor Innate Pharma's future filings for updates on the actual utilization of this $75.0 million offering, as significant sales could lead to share dilution.
Key Numbers
- $75.0 million — Maximum aggregate offering price (The total amount of ADSs Innate Pharma can sell under the program.)
Key Players & Entities
- Innate Pharma SA (company) — the registrant filing the 6-K
- Jefferies LLC (company) — sales agent for the equity offering program
- $75.0 million (dollar_amount) — aggregate offering price of the equity program
- April 26, 2023 (date) — date the Sales Agreement was entered into
- February 6, 2024 (date) — date of the 6-K report
Forward-Looking Statements
- Innate Pharma will utilize a portion of the $75.0 million 'at-the-market' offering in the next 12 months. (Innate Pharma SA) — medium confidence, target: February 6, 2025
FAQ
What is the purpose of Innate Pharma SA's 6-K filing dated February 6, 2024?
The 6-K filing serves to report on Innate Pharma SA's ongoing equity offering program, specifically confirming the Sales Agreement entered into on April 26, 2023, with Jefferies LLC for an "at-the-market" offering of up to $75.0 million in ADSs.
Who is the sales agent for Innate Pharma SA's equity offering program?
Jefferies LLC is the sales agent for Innate Pharma SA's equity offering program, as stated in the Sales Agreement dated April 26, 2023.
What is the maximum aggregate offering price for the American Depositary Shares (ADSs) under this program?
The maximum aggregate offering price for the American Depositary Shares (ADSs) under this program is up to $75.0 million, as detailed in the Sales Agreement.
When was the Sales Agreement for this equity offering program initially entered into?
The Sales Agreement with Jefferies LLC was initially entered into on April 26, 2023.
What does each American Depositary Share (ADS) represent for Innate Pharma SA?
Each American Depositary Share (ADS) represents one ordinary share of Innate Pharma SA, according to the filing.
Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-02-06 17:05:22
Key Financial Figures
- $75.0 million — ng an aggregate offering price of up to $75.0 million from time to time, through Jefferies as
Filing Documents
- innatepharma6-k262024.htm (6-K) — 22KB
- exhibit11-6xk020624.htm (EX-1.1) — 358KB
- exhibit51-6xk020624.htm (EX-5.1) — 50KB
- 0001628280-24-003515.txt ( ) — 431KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. By s Herv Brailly Date February 6, 2024 Name Herv Brailly Title Interim Chairman of the Executive Board and Chief Executive Officer